Haemonetics, trading under the ticker HAE, has finalized an agreement to divest its whole blood division to GVS. The deal is valued at up to $67.1 million, consisting of $44.6 million payable immediately and potential contingent earn-outs up to $22.5 million over the next four years. Under the terms of the agreement, GVS will take over Haemonetics' entire line of whole blood collection, processing, and filtration solutions. This includes the acquisition of the company's manufacturing facility in Covina, California, as well as associated equipment and assets positioned at Haemonetics' site in Tijuana, Mexico.
The revenue generated from this transaction is slated for general corporate purposes and further investments in initiatives aimed at fostering growth.
